-16.7%
NVO vs MRNA
+485.7%
-502.4%
-43.7%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -2.1% | +5.4% | -7.5% | -2.3% |
| 7D | -7.6% | -1.1% | -6.5% | -7.6% |
| 30D | -6.0% | +126.1% | -132.1% | -9.6% |
| 3M | -0.8% | +190.0% | -190.8% | -9.0% |
| 6M | +16.5% | +157.2% | -140.8% | +8.3% |
| YTD | -11.1% | +388.2% | -399.3% | -25.8% |
| 1Y | -16.7% | +467.0% | -483.8% | -33.6% |
| All | -16.7% | +485.7% | -502.4% | -33.6% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling